Page 265 - EJMO-9-3
P. 265

Eurasian Journal of
            Medicine and Oncology                                          Metastasis gene expression in colorectal cancer



            with the results obtained in this study, where AST levels   Funding
            were higher in the metastasis group than in the non-
            metastasis group (Table 2).                        None.
              Therapeutic  implications for targeting SNAI1, ZEB1,   Conflict of interest
            Slug, Twist, MTA3, and TNF-α or their  regulators   The authors declared that there were no conflict of interest
            show  promise.  Natural  compounds  sensitize  cells  to   in this work.
            chemotherapy by disrupting EMT and inhibiting cancer
            development, while  stromal inhibition of  SNAI1, ZEB1,   Author contributions
            Slug, Twist, MTA3, and TNF-α could mitigate pro-
            tumorigenic signaling. However, partial EMT states   Conceptualization: Adeodatus Yuda Handaya, Hendra
            may persist as  reservoirs for recurrence,  necessitating   Susanto
            combination therapies. As shown in Table 4, the markers   Formal analysis: All authors
            used in this study affect cancer development, as expressed   Investigation: All authors
            in the T, N, and M (stage) grading scores.         Methodology: Hendra Susanto, Adeodatus Yuda Handaya
                                                               Writing–original draft:  Adeodatus  Yuda  Handaya,  Moch
              In conclusion, SNAI1 emerges as the dominant        Sholeh
            EMT-TF in colon cancer, modulated by TNF-α and stromal   Writing–review & editing: Adeodatus Yuda Handaya, Moch
            interactions. ZEB1, Slug, and Twist play ancillary roles,   Sholeh
            while MTA3’s involvement remains speculative. Therapeutic
            strategies must account for SNAI1’s multifaceted regulation   Ethics approval and consent to participate
            and the complexity of the tumor microenvironment.   The participants consented to complete the informed
            However, we recognize several limitations in this study,   consent form for the clinical observational study. With
            including: (a) the lack of a comprehensive database for   the certificate of ethics number: KE/FK/0938/EC/2021,
            patient baseline data, and (b) the focus on profiling the   this clinical study was authorized by the IRB, Faculty
            expression of several markers in CRC patient tumors   of Medicine, Universitas Gadjah Mada, Indonesia, in
            without supporting or validating data from additional tests,   accordance with the Declaration of Helsinki.
            such as somatic mutation analysis. Future studies should
            involve larger sample sizes, comparisons across racial   Consent for publication
            groups of clinical patients, and further laboratory analysis.   Not applicable, because  the  respondents’  identities  have
            A  comprehensive correlational approach that includes   been completely masked, and they have also agreed in the
            microscopic, serological, and bioinformatics analysis will   “written consent to participate” section that the samples
            be essential to support these initial findings.    will be used for further research purposes.

            5. Conclusion                                      Availability of data
            Through this study, it was found that SNAI1, ZEB1, Slug,   All the datasets generated in the current study are available
            Twist, and TNF-α were associated with cancer progression   from the corresponding author based on reasonable
            toward metastasis, as their expression levels increased   request.
            accordingly. In contrast, MTA3, a known metastasis
            suppressor, showed relatively lower expressing during   References
            metastasis progression. In addition, SNAI1, ZEB1, Slug,
            Twist, and TNF-α were also correlated with BMI and AST   1.   Klimeck L, Heisser T, Hoffmeister M, Brenner H. Colorectal
                                                                  cancer: A health and economic problem. Best Pract Res Clin
            levels
                                                                  Gastroenterol. 2023;66:101839.
            Acknowledgments                                       doi: 10.1016/j.bpg.2023.101839
            The authors would like to express our deepest gratitude to   2.   Sharzehan  MAK,  Sito H,  Abdullah  N,  et  al.  Association
            the PhD Biotechnology team at Malang State University for   between  CYP2E1  polymorphisms  and  colorectal
            conducting this research, as well as to our partners from   cancer risk: A  systematic review and meta-analysis.  Sci
            the Division of Digestive Surgery, Department of Surgery,   Rep. 2022;12(1):20149.
            Faculty of Medicine, Public Health and Nursing, Gadjah      doi: 10.1038/s41598-022-24398-w
            Mada University, and Dr.  Sardjito General Hospital,   3.   Islam MR, Aziz MA, Shahriar M, Islam MS. Polymorphisms
            Yogyakarta, Indonesia, for their assistance with clinical   in IL-17A gene and susceptibility of colorectal cancer in
            support and respondent preparation.                   bangladeshi  population:  A  case-control  analysis.  Cancer


            Volume 9 Issue 3 (2025)                        257                         doi: 10.36922/EJMO025210202
   260   261   262   263   264   265   266   267   268   269   270